Executive · Scientist · Founder
Perry Nisen
Perry Nisen is a physician-scientist and CEO of Quanta Therapeutics, a South San Francisco biotech building next-generation oral KRAS inhibitors for RAS-driven cancers. A former pediatric oncologist turned pharma executive, he ran the GSK oncology portfolio later acquired by Novartis for over $16 billion, led the Sanford Burnham Prebys research institute, and serves on Teva's board. He now chases the 'undruggable' mutations that drive a quarter of all human cancers.